Please assess the completion status of the following clinical trial:

Trial Title: Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged from 18 to 65 years (inclusive).~* Able to walk and preform exercise program required by trial protocol.~* Body Mass Index (BMI) within the range of 30 to 45 kg/m2 (obese) with or without co-morbid conditions or greater than or equal to 27 and less than 30 kg/m2 (overweight) with at least one treated or untreated comorbid condition (hypertension, dyslipidemia, cardiovascular disease, untreated abnormal glucose metabolism, sleep apnea). For untreated co-morbid conditions, the condition must be considered by the Investigator as clinically stable.~* Prior to the study, patients should be able to voluntarily participate in this study and sign informed consent form approved by IRB/ICE~Exclusion Criteria:~* Not suitable to participate in the study in the opinion of the Investigator, including an existing physical or mental condition that prevents compliance with the protocol.~* Patients who had a history of Type 1 diabetes mellitus or confirmed diagnosis of Type 2 diabetes mellitus for more than 6 months.~* Recent history (within 1 years before entering the study) of major depression, anxiety, or other psychiatric disease requiring treatment with prescription medication (e.g., SSRI's, SNRI's \[including buproprion\], tricyclics, antipsychotics, lithium). Use of SSRI's and SNRI's (including buproprion) for reasons other than active psychiatric indications (e.g., migraine, weight loss, smoking cessation) must meet a 3-month washout.~* Total score on the Beck Depression Inventory-II (BDI-II) \> 20.~* Binge Eating Scale score \>17.~* History of epilepsy or other seizure disorder.~* Has done or anticipate Surgical procedure for the treatment of obesity (i.e., gastric bypass, gastric banding).~* Anticipation of surgery during the study period that may interfere with completion or compliance with the protocol.~* Uncontrolled hypertension after certain treatments, defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥ 100 mmHg.~* History of valve replacement surgery or CABG or other invasive cardiovascular surgical procedure. A diagnostic cardiac catheterization does not exclude.~* History of Myocardial infarction(MI), Cerebral Vascular Accident(CVA), or transient ischemic attack(TIA). Reversible ischemic neurological deficits (RIND), cardiac arrhythmia requiring medical or surgical treatment within 3 months of screening.~* Major surgical procedure (intrathoracic, intracranial, intraperitoneal, liposuction) within 6 months of screening~* History of unstable angina~* History of congestive heart failure caused by insufficiency or stenosis of any heart valve~* History of pulmonary artery hypertension~* Symptomatic untreated congestive heart failure of any etiology (stably treated NYHA class I or II CHF of ischemic or hypertensive etiology is acceptable)~* History of organ/bone marrow transplantation~* Abnormal TSH lab value \> 1.5x ULN~* Hyperthyroidism, including abnormal screening lab values with FT4 \> ULN and TSH \< LLN.~* Fasting triglycerides \> 499 mg/dL(5.64 mmol/L) ,if elevated at Screening, but not on a subsequent re-check, patient will be eligible. Otherwise, patients can't be enrolled.~* LDL-cholesterol ≥ 190 mg/dL(4.92 mmol/L).~* HbA1c greater than 9.0%~* Fasting glucose \> 270 mg/dL(11.0 mmol/L) ,if elevated at Screening, but not on a subsequent re-check, patient will be eligible. Otherwise, patients can't be enrolled.~* Clinically significant abnormal hepatic (e.g., AST or ALT \> 2.5x ULN, or total bilirubin \> 1.5x ULN) or renal function lab tests (e.g., creatinine \> 1.25x ULN) suggestive of hepatic or renal impairment.~* Positive result of HIV, hepatitis B or hepatitis C screens.~* Malignancy within 5 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins).~* Treatment with over-the counter weight loss products or appetite suppressants (including herbal weight loss agents) within 1 month of the screening visit, or with a prescription anti-obesity drug (phentermine, sibutramine, orlistat) or lipid dissolving injections within 3 months.~* Over 3 days of treatment with oral or parenteral corticosteroids within 2 weeks of the screening visit.~* Recent history (within 2 years prior to the screening visit) of alcohol or drug abuse.~* Significant change in smoking habits within 3 months prior to screening.~* Participated in any clinical study with an investigational drug, biologic, or device within 3 month prior to screening.~* Significant change in diet or level of physical activity or change in weight of \> 5 kg within 3 month prior to screening.~* Use of liquid weight loss diet within 6 months prior to screening.~* Disagree to continue to use an accepted method of birth control during and for at least 3 months after last study medication administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lorcaserin 10 mg BID (Type: EXPERIMENTAL): Lorcaserin 10 mg tablet each morning and evening
- Matching Placebo BID (Type: PLACEBO_COMPARATOR): Matching Placebo tablet each morning and evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues